Volume 5.36 | Sep 26

Prostate Cell News 5.36 September 26, 2014
Prostate Cell News
     In this issue: Publications | Reviews | Science News | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  PCN on Twitter
Single Luminal Epithelial Progenitors Can Generate Prostate Organoids in Culture
Organoids generated from CARNs (castration-resistant Nkx3.1-expressing cells) or normal prostate epithelia exhibit tissue architecture containing luminal and basal cells, undergo long-term expansion in culture and exhibit functional androgen receptor signalling. [Nat Cell Biol] Abstract
Free Wallchart | Assays for Human Mammary Stem and Progenitor Cells
PUBLICATIONS (Ranked by impact factor of the journal)

MicroRNA Expression Profile of Primary Prostate Cancer Stem Cells as a Source of Biomarkers and Therapeutic Targets
Investigators discovered concordance between the microRNA expression profiles of unfractionated epithelial cells from castration-resistant prostate cancer, human embryonic stem cells (SCs), and prostate epithelial SCs (both benign and malignant). [Eur Urol] Abstract

Plk1 Inhibition Enhances the Efficacy of Androgen Signaling Blockade in Castration-Resistant Prostate Cancer
Scientists show that oxidative stress activates both the PI3K/AKT/mTOR pathway and androgen receptor (AR) signaling in a polo-like kinase 1 (Plk1)-dependent manner in prostate cells. Inhibition of the PI3K/AKT/mTOR pathway prevented oxidative stress-induced activation of AR signaling. [Cancer Res] Abstract

UAP1 Is Overexpressed in Prostate Cancer and Is Protective against Inhibitors of N-Linked Glycosylation
Investigators analyzed 3261 prostate cancers on a tissue microarray and found that UDP-N-acetylglucosamine pyrophosphorylase 1 (UAP1) staining correlates negatively with Gleason score and positively with high androgen receptor expression. [Oncogene] Abstract

Role of the Phospholipase A2 Receptor in Liposome Drug Delivery in Prostate Cancer Cells
The authors examined phospholipase A2 receptor (PLA2R1) expression in primary prostate cells and human prostate cancer cells, and they determined the effect of PLA2R1 knockdown on cytotoxicity induced by free or liposome-encapsulated chemotherapeutics. [Mol Pharm] Abstract

INPP4B Suppresses Prostate Cancer Cell Invasion
The authors demonstrate that de novo expression of INPP4B in highly invasive human prostate carcinoma PC-3 cells suppresses their invasion both in vitro and in vivo. Using global gene expression analysis, they found that INPP4B regulates a number of genes associated with cell adhesion, the extracellular matrix, and the cytoskeleton. [Cell Commun Signal] Abstract | Full Article

A Role for STEAP2 in Prostate Cancer Progression
Quantitative analysis of six transmembrane epithelial antigen of the prostate (STEAP) 1 and 2 gene expression were statistically significantly associated with the metastatic cell lines DU145 and PC3 as compared to the normal prostate epithelial cell line, PNT2. [Clin Exp Metastasis] Abstract

In Vitro Evaluation of Novel N-Acetylalaninate Prodrugs that Selectively Induce Apoptosis in Prostate Cancer Cells
To evaluate chiral ester prodrugs, researchers monitored cellular glutathione depletion, cellular protein carbonyl levels (an oxidative stress biomarker) and cell viability in tumorigenic and nontumorigenic prostate cancer cell lines. [BMC Cancer] Full Article


Abiraterone Acetate for Patients with Metastatic Castration-Resistant Prostate Cancer Progressing after Chemotherapy: Final Analysis of a Multicenter, Open-Label, Early-Access Protocol Trial
Researchers present the final analysis of an early-access protocol trial that was initiated after completion of COU-AA-301 to enable worldwide preapproval access to abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after chemotherapy. [Lancet Oncol] Abstract

A Phase II Trial of a Combination Herbal Supplement for Men with Biochemically Recurrent Prostate Cancer
Men previously treated for prostate cancer with surgery, radiation or both with rising PSA but no radiographic metastases were treated with three capsules of Prostate Health Cocktail daily; the primary end point was 50% PSA decline. [Prostate Cancer Prostatic Dis] Abstract

[Free On-Demand Webinar] Potential Applications of ALDH+ Cells in Regenerative Medicine - Watch Now.
Bone-Targeting Radiopharmaceuticals for the Treatment of Bone-Metastatic Castration-Resistant Prostate Cancer: Exploring the Implications of New Data
The authors review the merits, applications, and limitations of emerging data sets on bone-metastatic castration-resistant prostate cancer with a focus on radium-223, an α-emitting radiopharmaceutical, and its use in therapy for this disease. [Oncologist] Abstract

Visit our reviews page to see a complete list of reviews in the prostate cell research field.
Tokai Pharmaceuticals Announces Updated Phase II Data on Galeterone in Patients with Advanced Prostate Cancer
Tokai Pharmaceuticals, Inc. announced that updated, interim results from the company’s ongoing Phase II clinical trial, ARMOR2, of its lead drug candidate, galeterone, in patients with castration resistant prostate cancer will be presented. [Press release from Tokai Pharmaceuticals, Inc. discussing research to be presented at the European Society for Medical Oncology (ESMO) 2014 Congress, Madrid ] Press Release

From our sponsor: Pluripotent cell isolation for regenerative medicine. Request a free wallchart from Nature.
NuView Life Sciences Enters Global Licensing Agreement with Otsuka Pharmaceutical
NuView Life Sciences, Inc. announced entry into an exclusive global licensing and collaboration agreement with Otsuka Pharmaceutical Co., Ltd. to further develop and commercialize NuView’s investigative genomic-based diagnostic biomarker to detect cancers of the breast and prostate. [NuView Life Sciences, Inc. (PR Newswire Association LLC)] Press Release

UR Awarded $18 Million for Cancer Control Studies; Grant Among Largest in Decade
As a result of longstanding research strength, the Cancer Control & Survivorship program at University of Rochester (UR) Medicine’s Wilmot Cancer Institute has been selected to receive an $18.6 million, five-year grant for a leadership role in a nationwide clinical research network to investigate cancer-related side effects. [University of Rochester] Press Release
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
NEW CellTech India 2015
March 2-3, 2015
Bangalore, India

Visit our events page to see a complete list of events in the prostate cell community.
NEW Postdoctoral Positions – Prostate Biology and Cancer Cell and Molecular Biology (State University of Campinas)

NEW Research Assistant – Clinical Prostate Cancer Research Group (Garvan Institute of Medical Research)

Postdoctoral Fellows and Graduate Student Positions (Vancouver Prostate Centre)

Postdoctoral Scientist – Prostate Oncobiology (Cancer Research UK – Manchester Institute)

Postdoctoral Position – Prostate Cancer Research (Umeå University)

Postdoctoral Positions – Prostate Metastasis Evolution (Cold Spring Harbor Laboratory)

Postdoctoral Fellowship Position – Cancer Immunology (Cornell University)

Postdoctoral Fellow – Prostate Cancer (Cleveland Clinic)

Scientist – Prostate Cell Research (STEMCELL Technologies Inc.)

Scientist – Cell Culture Support Products (STEMCELL Technologies Inc.)

Scientist – Immunology/Cell Separation (STEMCELL Technologies Inc.)

Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Prostate Cell News? Click here to submit!

Comments or suggestions? Submit your feedback here
Learn more about Prostate Cell News: Archives | Events | Contact Us